The global pressure ulcers market revenue was around US$ 4.01 billion in 2023 and is estimated to reach US$ 5.85 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.2% during the forecast period from 2024 to 2032.
Pressure ulcers are decubitus ulcers or pressure sores are injuries to the tissue and skin. This is due to the prolonged pressure with friction on the skin. They occur most typically on the skin present over heels, sacrum, coccyx, and hips.
Market Driving Factors
The surge in the prevalence of pressure ulcers worldwide is estimated to boost the market growth. Several factors such as a sedentary lifestyle, advancing age, mobility problems, and different health conditions have been responsible for the surge in the prevalence of pressure ulcers. For instance, according to the National Center for Biotechnology Information, pressure ulcers are the third most expensive illness after cardiovascular disorders and cancer. The mortality rates from this illness are two to six times higher than those from other disorders, with 60,000 deaths annually from this consequence.
An increase in the geriatric population is predicted to boost the market growth. This is because the elderly are more sensitive to the development of skin lesions due to the changes associated with the aging process. Prolonged life expectancy surges the number of individuals aged over 80 years, thus being placed at a higher chance of disability and immobility. For instance, according to the National Center for Biotechnology Information, older patients are more inclined to sacral decubitus ulcers, and two-thirds of pressure ulcers happen in patients older than 70 years. Some data show that 83% of hospitalized patients developed ulcers within five days of hospitalization.
Costly treatments for pressure ulcers are predicted to hamper the market growth.
Regional Analysis
North America dominated the market in terms of the largest shares and is estimated to maintain its dominance during the forecast period. This can be attributed to the surge in the demand for wound care devices and dressing products for pressure ulcer treatments. Furthermore, there is a surging prevalence of pressure ulcers, a rise in the number of approvals for pressure ulcer treatment drugs, and a strong existence of key players. Thus, this factor is expected to drive the market growth.
Asia-Pacific is estimated to dominate the market in terms of the growth rate. This is mainly owing to the surge in the prevalence of pressure ulcers, increase in patients seeking treatments for pressure ulcers, rise in geriatric populations, and increase in healthcare expenditure which will drive the market growth. For instance, according to the Asian Development Bank, Asia's geriatric population is estimated to reach nearly 923 million by the middle of this century. As a result, this region has the potential to rank among the oldest in the world within the next several decades. Furthermore, due to the increasing senior citizen population, the pressure ulcer disease will increase.
Segmentation Insights
Treatment Type Insight
The wound care devices segment is estimated to dominate the market in terms of revenue. This is mainly owing to the surge in the adoption of cutting-edge wound devices for the treatment of pressure ulcer wounds. Additionally, an effective product range launched by firms ensures more suitable therapeutic outcomes as compared to conventional methods. Thus, this is estimated to drive the market growth.
End User Insight
The hospital segment is estimated to dominate the market in terms of the largest shares. This can be due to the hospital are increase in the showing an inclination toward cutting-edge wound care products. Additionally, rise in the investments by hospitals in cutting-edge wound care products to decrease hospital stay and to curb the overall price burden by decreasing the longer hospital stay of patients. Therefore, this is estimated to boost the market growth.
Prominent Companies
Segmentation Outline
The global pressure ulcers market segmentation focuses on the Type, Treatment Type, End User, and Region.
By Type
By Treatment Type
By End User
By Region
[ TABLE OF CONTENT ]
1 INTRODUCTION OF GLOBAL PRESSURE ULCERS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: PRESSURE ULCERS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL PRESSURE ULCERS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL PRESSURE ULCERS MARKET, BY TYPE
5.1 OVERVIEW
5.2 STAGE 1
5.3 STAGE 2
5.4 STAGE 3
5.5 STAGE 4
5.6 DEEP TISSUE INJURY
6 GLOBAL PRESSURE ULCERS MARKET, BY TREATMENT TYPE
6.1 OVERVIEW
6.2 WOUND CARE DRESSING
6.3 FOAM DRESSINGS
6.3.1 HYDROCOLLOID DRESSINGS
6.3.2 ALGINATE DRESSINGS
6.3.3 OTHER DRESSINGS
6.4 WOUND CARE DEVICES
6.4.1 THERAPY DEVICES
6.4.2 OTHERS
7 GLOBAL PRESSURE ULCERS MARKET, BY END USER
7.1 OVERVIEW
7.2 HOSPITALS
7.3 HOMECARE
7.4 OTHERS
8 GLOBAL PRESSURE ULCERS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL PRESSURE ULCERS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 3M COMPANY
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 CARDINAL HEALTH INC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ESSITY
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 COLOPLAST GROUP
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 TISSUE REGENIX
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 SMITH & NEPHEW PLC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 B. BRAUN MELUNGEON AG
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 SHANDONG CHUANGKANG BIOTECHNOLOGY CO. LTD
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 ANHUI JINYE INDUSTRIAL CO. LTD
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 WEGO CHEMICAL GROUP
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 INVESTOR AB
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 STRYKER CORPORATION
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 ABERCROMBIE & FITCH CO
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 INTEGRA LIFESCIENCES
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 BAXTER INTERNATIONAL
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 CONVATEC GROUP PLC
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
著作権 ©2022 無断複写・転載を禁じます